



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3 Attorney Docket Number 28967/5794C

**Complete If Known**

Application Number	10/522,232-Conf. #1644
Filing Date	July 8, 2005
First Named Inventor	McColl et al.
Art Unit	1647
Examiner Name	Christine J. Saoud

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
A1	4,645,668	02-24-1987	Pinnell		
A2	5,304,118	04-19-1994	Trese et al.		

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
B1	GB 985,498		03-10-1965	Novo Terapeutisk Labor AS		
B2	WO 1991/11193		08-08-1991	Children's Hospital		
B3	WO 1995/24473		09-14-1995	Human Genome Sciences, Inc.		
B4	WO 1996/11269		04-18-1996	Regeneron Pharmaceuticals, Inc.		
B5	WO 1996/26736		09-06-1996	Ludwig Institute for Cancer Research Helsinki University Licensing Ltd., OY		
B6	WO 1998/07832		02-26-1998	Ludwig Institute for Cancer Research		
B7	WO 2000/18436		04-06-2000	Leuven Research & Development VZW		
B8	WO 2001/62799		08-30-2001	Universitair Medisch Centrum Utrecht		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
C1	ACHEN et al., Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis, J. Pathol., 193:147-154, 2001.		
C2	ACHEN et al., Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3, Eur. J. Biochem., 267:2505-2515, 2000.		
C3	ACHEN et al., Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4), PNAS USA, 95:548-553, 1998.		
C4	ANDREASEN et al., The plasminogen activation system in tumor growth, invasion, and metastasis, Cell. Mol. Life Sci., 57:25-40, 2000.		
C5	BALDWIN et al., Multiple forms of mouse vascular endothelial growth factor-D are generated by RNA splicing and proteolysis, J. Biol. Chem., 276:44307-44314, 2001.		

Examiner Signature	Date Considered
--------------------	-----------------

950130

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/522,232-Conf. #1644
<i>(Use as many sheets as necessary)</i>				Filing Date	July 8, 2005
				First Named Inventor	McColl et al.
				Art Unit	1647
				Examiner Name	Christine J. Saoud
Sheet	2	of	3	Attorney Docket Number	28967/5794C

C6	BELL, The fibrinolytic system in neoplasia, Seminars in Thrombosis and Hemostasis, 22:459-478, 1996.	
C7	BROWN et al., Biotinylated and cysteine-modified peptides as useful reagents for studying the inhibition of cathepsin G, Anal. Biochem., 217:139-147, 1994.	
C8	BUGGE et al., Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice, Blood, 90:4522-4531, 1997.	
C9	BYZOVA et al., Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns <i>in vivo</i> , Blood, 99:4434-4442, 2002.	
C10	CAO et al., Vascular endothelial growth factor C induces angiogenesis <i>in vivo</i> , PNAS USA, 95:14389-14394, 1998.	
C11	CARMELIET et al., Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system, Ann. N.Y. Acad. Sci., 811:191-206, 1997.	
C12	COLLEN et al., Basic and clinical aspects of fibrinolysis and thrombolysis, Blood, 78:3114-3124, 1991.	
C13	CONNOLLY, Vascular permeability factor: a unique regulator of blood vessel function, J. Cell. Biochem., 47:219-223, 1991.	
C14	ENHOLM et al., Vascular endothelial growth factor-C: a growth factor for lymphatic and blood vascular endothelial cells, Trends Cardiovasc. Med., 8:292-297, 1998.	
C15	FERRARA et al., The vascular endothelial growth factor family of polypeptides, J. Cell. Biochem., 47:211-218, 1991.	
C16	FOLKMAN et al., Angiogenesis, J. Biol. Chem., 267:10931-10934, 1992.	
C17	HE et al., Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling, J. Natl. Cancer Inst., 94:819-825, 2002.	
C18	HOUCK et al., Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms, J. Biol. Chem., 267:26031-26037, 1992.	
C19	JOUKOV et al., A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases, EMBO J., 15:290-298, 1996.	
C20	JOUKOV et al., Proteolytic processing regulates receptor specificity and activity of VEGF-C, EMBO J., 16:3898-3911, 1997.	
C21	KAIPAINEN et al., Enhanced expression of the tie receptor tyrosine kinase messenger RNA in the vascular endothelium of metastatic melanomas, Cancer Res., 54:6571-6577, 1994.	
C22	KAIPAINEN et al., Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development, PNAS USA, 92:3566-3570, 1995.	
C23	MANDRIOTA et al., Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis, EMBO J., 20:672-682, 2001.	
C24	MARCONCINI et al., c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis <i>in vivo</i> and <i>in vitro</i> , PNAS USA, 96:9671-9676, 1999.	
C25	MUELLER et al., Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice, PNAS USA, 92:205-209, 1995.	
C26	NAKAMURA et al., Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up, Clin. Cancer Res., 9:716-721, 2003.	
C27	OLOFSSON et al., Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells, PNAS USA, 95:11709-11714, 1998.	
C28	OLOFSSON et al., Vascular endothelial growth factor B, a novel growth factor for endothelial cells, PNAS USA, 93:2576-2581, 1996.	
C29	PAAVONEN et al., Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing, Am. J. Pathol., 156:1499-1504, 2000.	
C30	PARTANEN et al., VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues, FASEB J., 14:2087-2096, 2000.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

950130

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/522,232-Conf. #1644
<i>(Use as many sheets as necessary)</i>				Filing Date	July 8, 2005
				First Named Inventor	McColl et al.
				Art Unit	1647
				Examiner Name	Christine J. Saoud
Sheet	3	of	3	Attorney Docket Number	28967/5794C

C31	PLOUËT et al., Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect, <i>J. Biol. Chem.</i> , 272:13390-13396, 1997.	
C32	SKOBE et al., Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis, <i>Nat. Med.</i> , 7:192-198, 2001.	
C33	STACKER et al., A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability, <i>J. Biol. Chem.</i> , 274:34884-34892, 1999.	
C34	STACKER et al., Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers, <i>J. Biol. Chem.</i> , 274:32127-32136, 1999.	
C35	STACKER et al., The role of tumor lymphangiogenesis in metastatic spread, <i>FASEB J.</i> , 16:922-934, 2002.	
C36	STACKER et al., VEGF-D promotes the metastatic spread of tumor cells via the lymphatics, <i>Nat. Med.</i> , 7:186-191, 2001.	
C37	SZUBA et al., Therapeutic lymphangiogenesis with human recombinant VEGF-C, <i>FASEB J.</i> , 16:1985-1987, 2002.	
C38	VEIKKOLA et al., Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice, <i>EMBO J.</i> , 20:1223-1231, 2001.	
C39	WANG et al., Induction of KDR expression in bovine arterial endothelial cells by thrombin: involvement of nitric oxide, <i>J. Cell. Physiol.</i> , 190:238-250, 2002.	
C40	WHITE et al., Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma, <i>Cancer Res.</i> , 62:1669-1675, 2002.	
C41	WISE et al., Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1, <i>PNAS USA</i> , 96:3071-3076, 1999.	
C42	YAO et al., Age and growth factors in porcine full-thickness wound healing, <i>Wound Repair Regen.</i> , 9:371-377, 2001.	
C43	YOKOYAMA et al., Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma, <i>Br. J. Cancer</i> , 88:237-244, 2003.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./

Examiner Signature	/Christine Saoud/	Date Considered	01/22/2008
--------------------	-------------------	-----------------	------------

950130